JP2017535548A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535548A5 JP2017535548A5 JP2017525946A JP2017525946A JP2017535548A5 JP 2017535548 A5 JP2017535548 A5 JP 2017535548A5 JP 2017525946 A JP2017525946 A JP 2017525946A JP 2017525946 A JP2017525946 A JP 2017525946A JP 2017535548 A5 JP2017535548 A5 JP 2017535548A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- expression
- level
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 97
- 201000011510 cancer Diseases 0.000 claims 65
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 53
- 239000003814 drug Substances 0.000 claims 46
- 238000000034 method Methods 0.000 claims 35
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 28
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 28
- 239000005557 antagonist Substances 0.000 claims 22
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 19
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 19
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 229960001592 paclitaxel Drugs 0.000 claims 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 8
- 229930012538 Paclitaxel Natural products 0.000 claims 7
- 229940127089 cytotoxic agent Drugs 0.000 claims 7
- 230000004083 survival effect Effects 0.000 claims 7
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 230000000973 chemotherapeutic effect Effects 0.000 claims 5
- 229960000303 topotecan Drugs 0.000 claims 5
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- -1 EMD-7200 Substances 0.000 claims 4
- 229960004562 carboplatin Drugs 0.000 claims 4
- 190000008236 carboplatin Chemical compound 0.000 claims 4
- 238000009104 chemotherapy regimen Methods 0.000 claims 4
- 230000002055 immunohistochemical effect Effects 0.000 claims 4
- 229960004768 irinotecan Drugs 0.000 claims 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 229910052697 platinum Inorganic materials 0.000 claims 4
- 238000010837 poor prognosis Methods 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 3
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 206010047741 Vulval cancer Diseases 0.000 claims 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 229960004117 capecitabine Drugs 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 229960004679 doxorubicin Drugs 0.000 claims 3
- 229960001756 oxaliplatin Drugs 0.000 claims 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 3
- 201000002628 peritoneum cancer Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 206010046885 vaginal cancer Diseases 0.000 claims 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims 3
- 201000005102 vulva cancer Diseases 0.000 claims 3
- NECZZOFFLFZNHL-XVGZVFJZSA-N (2s)-2-amino-5-[[(2r)-3-[2-[bis[bis(2-chloroethyl)amino]-oxidophosphaniumyl]oxyethylsulfonyl]-1-[[(r)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 NECZZOFFLFZNHL-XVGZVFJZSA-N 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 229940124638 COX inhibitor Drugs 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 208000010201 Exanthema Diseases 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 206010028813 Nausea Diseases 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 229940078123 Ras inhibitor Drugs 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 108700011582 TER 286 Proteins 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 230000003388 anti-hormonal effect Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 229950000772 canfosfamide Drugs 0.000 claims 2
- 229940045200 cardioprotective agent Drugs 0.000 claims 2
- 239000012659 cardioprotective agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 201000005884 exanthem Diseases 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 230000003394 haemopoietic effect Effects 0.000 claims 2
- 230000002631 hypothermal effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 230000008693 nausea Effects 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010037844 rash Diseases 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462079787P | 2014-11-14 | 2014-11-14 | |
| US62/079,787 | 2014-11-14 | ||
| PCT/US2015/059733 WO2016077227A2 (en) | 2014-11-14 | 2015-11-09 | Predicting response to a vegf antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017535548A JP2017535548A (ja) | 2017-11-30 |
| JP2017535548A5 true JP2017535548A5 (enExample) | 2018-12-20 |
Family
ID=54754748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525946A Pending JP2017535548A (ja) | 2014-11-14 | 2015-11-09 | Ｖｅｇｆアンタゴニストの応答の予測 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20170226198A1 (enExample) |
| EP (1) | EP3218401B1 (enExample) |
| JP (1) | JP2017535548A (enExample) |
| KR (1) | KR20170082537A (enExample) |
| CN (1) | CN107106688A (enExample) |
| AR (1) | AR102647A1 (enExample) |
| AU (1) | AU2015346652A1 (enExample) |
| BR (1) | BR112017009633A2 (enExample) |
| CA (1) | CA2966216A1 (enExample) |
| HK (1) | HK1242996A1 (enExample) |
| IL (1) | IL251947A0 (enExample) |
| MX (1) | MX2017006201A (enExample) |
| RU (1) | RU2017120388A (enExample) |
| SG (1) | SG11201703744VA (enExample) |
| WO (1) | WO2016077227A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108753984B (zh) * | 2018-08-28 | 2021-07-13 | 北京市神经外科研究所 | 预测或诊断脑恶性胶质瘤术后复发的生物标志物组合及其应用和试剂盒 |
| WO2021156137A1 (en) * | 2020-02-04 | 2021-08-12 | Oslo Universitetssykehus Hf | Biomarkers predicting clinical response of a vegf-a inhibitory drug in cancer patients, method for their selection and use |
| CA3175129A1 (en) * | 2020-03-12 | 2021-09-19 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2024028846A1 (en) * | 2022-08-05 | 2024-02-08 | Geistlich Pharma Ag | Combination therapy for treating cancers |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4619651B2 (ja) * | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
| US20040191218A1 (en) * | 2001-09-26 | 2004-09-30 | Emlen James W | Pharmaceutical compositions and methods for treating cancer |
| CA2517074A1 (en) * | 2003-02-27 | 2004-09-10 | Yeda Research And Development Co., Ltd. | Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection |
| EP2583685A1 (en) * | 2004-06-10 | 2013-04-24 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of human cancer |
| JP2012501188A (ja) * | 2008-08-29 | 2012-01-19 | ジェネンテック， インコーポレイテッド | Ｖｅｇｆ非依存性腫瘍についての診断薬および治療 |
| CN102711830A (zh) * | 2010-01-19 | 2012-10-03 | 霍夫曼-拉罗奇有限公司 | 用于贝伐单抗联合疗法的基于肿瘤组织的生物标志 |
| AU2011221229B2 (en) * | 2010-02-23 | 2015-06-18 | F. Hoffmann-La Roche Ag | Anti-angiogenesis therapy for the treatment of ovarian cancer |
| CN103140761B (zh) * | 2010-07-19 | 2015-11-25 | 霍夫曼-拉罗奇有限公司 | 贝伐单抗组合疗法用于治疗胰腺癌的血浆生物标志物 |
| SG10201505593VA (en) * | 2010-07-19 | 2015-09-29 | Hoffmann La Roche | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| EP2596363B1 (en) * | 2010-07-19 | 2017-01-18 | F. Hoffmann-La Roche AG | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| CN103339508A (zh) * | 2010-12-09 | 2013-10-02 | 霍夫曼-拉罗奇有限公司 | Agtr1作为贝伐单抗联合疗法的标志物 |
| WO2012118969A2 (en) * | 2011-03-01 | 2012-09-07 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Method of selecting cancer patients for anti-angiogenesis therapy in combination with chemotherapy |
| AR089067A1 (es) * | 2011-12-05 | 2014-07-30 | Hoffmann La Roche | Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama |
-
2015
- 2015-11-09 KR KR1020177013270A patent/KR20170082537A/ko not_active Withdrawn
- 2015-11-09 JP JP2017525946A patent/JP2017535548A/ja active Pending
- 2015-11-09 CN CN201580070085.3A patent/CN107106688A/zh active Pending
- 2015-11-09 WO PCT/US2015/059733 patent/WO2016077227A2/en not_active Ceased
- 2015-11-09 BR BR112017009633A patent/BR112017009633A2/pt not_active IP Right Cessation
- 2015-11-09 RU RU2017120388A patent/RU2017120388A/ru not_active Application Discontinuation
- 2015-11-09 AU AU2015346652A patent/AU2015346652A1/en not_active Abandoned
- 2015-11-09 EP EP15802244.2A patent/EP3218401B1/en active Active
- 2015-11-09 SG SG11201703744VA patent/SG11201703744VA/en unknown
- 2015-11-09 MX MX2017006201A patent/MX2017006201A/es unknown
- 2015-11-09 CA CA2966216A patent/CA2966216A1/en not_active Abandoned
- 2015-11-09 HK HK18102570.4A patent/HK1242996A1/zh unknown
- 2015-11-13 AR ARP150103707A patent/AR102647A1/es unknown
-
2017
- 2017-04-26 IL IL251947A patent/IL251947A0/en unknown
- 2017-04-28 US US15/581,448 patent/US20170226198A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lordick et al. | Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial | |
| JP2018508183A5 (enExample) | ||
| Walker et al. | Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? | |
| Clarke et al. | Understanding and targeting resistance to anti-angiogenic therapies | |
| Røsland et al. | Novel points of attack for targeted cancer therapy | |
| Goldman et al. | Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib | |
| Seeber et al. | Targeted therapy of colorectal cancer | |
| Ferté et al. | IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy | |
| Lim et al. | CDK4/6 inhibitors: promising opportunities beyond breast cancer | |
| Sun et al. | Gastric cancer: current and evolving treatment landscape | |
| Ayyappan et al. | Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer | |
| Alese et al. | Update on emerging therapies for advanced colorectal cancer | |
| Gilbert et al. | A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma | |
| Souglakos et al. | Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) | |
| Nikolaou et al. | The role of neurotensin and its receptors in non-gastrointestinal cancers: A review | |
| RU2017125054A (ru) | Композиции и способы лечения и диагностики резистентного к химиотерапии рака | |
| Basu et al. | Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer | |
| JP2015514113A (ja) | 単一特異性および二重特異性抗ｉｇｆ−１ｒおよび抗ｅｒｂｂ３抗体の用法および用量 | |
| Perez et al. | A view on EGFR-targeted therapies from the oncogene-addiction perspective | |
| Li et al. | Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway | |
| Chen et al. | The clinical application of fruquintinib on colorectal cancer | |
| JP7579636B2 (ja) | 膵がん治療のための組み合わせ治療薬 | |
| Jeong et al. | Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer | |
| Shimizu et al. | Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer | |
| JP2017535548A5 (enExample) |